STOCKS TELEGRAPH

Tag: CVM STOCK PRICE

  • Is There Any Reason As To Why The CVM Stock Plunged In Premarket Session?

    Is There Any Reason As To Why The CVM Stock Plunged In Premarket Session?

    At last check, CEL-SCI Corporation (CVM) shares were down -5.65% to trade at $8.19 in pre-market trading. During Wednesday’s trading session, CEL-SCI stock rose 8.50% to $8.68. CVM stock volume was 7.55 million shares, compared to the one million shares averaged over the past 50 days. In the past week, CVM shares have moved down by -32.35%. The company’s shares have fallen by -37.01% over the last 12 months.

    Over the past three months, shares have fallen -46.72%, while over the last six months they fell -30.67%. A total of 40.05 million shares were outstanding as of the end of June, with the market capitalization of CVM standing at $398.67 million. CVM’s stock has been losing ground even after it sent a letter to shareholders clarifying the confusion surrounding one of its studies.

    What did CVM write to shareholders?

    CEL-SCI believes that encouraging an immune system boost while it is still intact will provide the greatest benefit to a patient. Thus, in the Phase 3 study, CVM used its investigational product Multikine first and BEFORE surgery and radiotherapy, or surgery and concurrent radiotherapy and chemotherapy, for those newly diagnosed with advanced primary squamous cell carcinoma of the head and neck. With its unique approach, CVM stands out from the competition. For patients receiving Multikine plus radiation and surgery, the study demonstrated excellent survival results. The survival benefit was negated when chemotherapy was added.

    CEL-SCI sent out a shareholder letter yesterday to clarify some confusion about CVM’s Phase 3 study results announced last week.

    Here are some highlights of the letter:

    • As a result of CVM’s Multikine immunotherapy, the world’s largest Phase 3 study of newly diagnosed advanced primary head and neck cancer demonstrated a statistically significant survival benefit of 14.1% after receiving surgery and radiotherapy.
    • A CVM study involves about 155,000 patients per year and 40% of the total study population.
    • CVM noted that there appears to be confusion concerning whether data from one of the 2 potential treatment arms is adequate for approval despite the fact that it shows benefits for its patients.
    • As explained by CVM, the protocol stipulated that the analysis for the successful treatment arm must be conducted before the unblinding.
    • CVM can use this data to seek FDA approval for its successful treatment.
    • This data has been reviewed by CVM and deemed safe, and it knows that it can be used in seeking FDA approval based on this data.
    • CVM’s Phase 3 results showed that this treatment arm’s overall survival (OS) benefit was robust and durable for five years, without any safety issues, something that is uncommon for cancer drugs.
    • At 5-years, Multikine-treated patients had a 14.1% absolute advantage over the unknown control group in overall survival, according to CVM.

    How CVM is planning to move forward?

    CEL-SCI (CVM) announced results from a Phase 3 study on June 28, 2021, which showed that Multikine achieved all of the protocol requirements stated in the study protocol in patients receiving surgery and radiation as their standard therapies. CVM will apply for and seek FDA approval to use Multikine in this patient population for the treatment of advanced primary head and neck cancer.

  • The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    In the current trading session, CEL-SCI Corporation (CVM) stock surged by 20.45% to the price of $24.15 at the time of writing. CVM stock closed Wednesday’s session at $20.05 which is a gain. The stock volume traded today for 6.17 million shares. The shares exchanged hands five times the average volume of trade for the past 3 months. For the past year, CVM stock soared by 75.42%, and the past week it had also jumped 19.42%. In the past three and six months, the stock has gained 38.75%and 33.67% respectively. Furthermore, CEL-SCI is currently valued in the market at $766.11 million and has 40.53 million outstanding shares.

    Biotech Investors are hinging on the success of Multikine phase 3

    CEL-SCI stock rallied up to 45% this week. The boost is coming due to the gathering of results for the advancement in the phase III trial of its flagship investigational product Multikine.

    On similar news related to Multikine, the company had seen a whopping gain of 82% in the month of January (on 26th) which was correlated with the WallStreetBets rally. Multikine is the only late-stage candidate of CVM stock and the reason behind the surge was the tweet by Geert Kersten – CEO of CEL-SCI which hyped up news about Multikine Phase III data’s release.

    However, the news of the release of data had dragged on even passing the month of February, in which the Kerstentold the investors to keep their head high for the data and have confidence in the stock. Now the hype is aired around the full data analysis readout for the clinical study of immunotherapy. Success of this lead investigative product will lead to a life-changing course of action for patients with squamous cell carcinoma in the head or the neck.

    Where will the success of Multikline lead the company?

    The success of phase III Multikline will move the company to a phase where it can commercialize this treatment and boost the value of the CVM stock. Furthermore, the company will become an attractive buyout candidate for big pharma companies waiting to gain the benefits of its future potential.

    CES-SCI’s lead product offering and operational background

    CEL-SCI Corporation is a biotechnology company that specifically focuses on the design and development of novel treatments that are offered to target the demands and unmet needs of patients with certain diseases. The biotech company aims to develop immunotherapies for the treatment of infectious diseases as well as cancer. The leading investigational immunotherapy of CEL-SCI is Multikine. Multikine is being developed for the treatment of head and neck cancer. The immunotherapy is currently under clinical phase III trial.

    CEL-SCI has also created a T-cell modulation procedure that can trigger the immune system to fight bacterial, parasitic and viral infections. The process is done by the system known as LEAPS which stands for Ligand Epitope Antigen Presentation System. LEAPS also focuses on the countering of autoimmune diseases, cancer, and allergies. The company uses this LEAPS system for a different platform which includes the treatment of rheumatoid arthritis and even a product candidate for coronavirus.